Back to NVSView Full LandscapeView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
2
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
11 competitors in Polycythemia Vera
VERADISC-3405
INCYruxolitinib tablets
Phase 3PRTXPlacebo
Phase 3PRTXOpen-label rusfertide
Phase 3INCYHydroxyurea (HU)
Phase 3Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA7/1/2019
Xromi
Xromi is indicated for the prevention of vaso-occlusive complications of Sickle Cell Disease in patients over 9 months of age.
View on EMAEMA6/29/2007
Siklos
Siklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in paediatric and adult patients suffering from symptomatic sickle-cell syndrome.
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
Peg-alpha interferon (Peg-Intron)Phase 3
Leukemia, Myeloid, Chronic
cyclosporin + mycophenolate mofetilPhase 3
Kidney Failure
Imatinib Mesylate (Gleevec)Phase 3
Idiopathic Pulmonary Fibrosis
GP2017 (adalimumab biosimilar)Phase 3
Ankylosing Spondylitis
Nilotinib (Tasigna ®)Phase 3
Chronic Myeloid Leukemia
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts